and oxidation via the cytochrome, P450-dependent, mixed- function oxidase enzyme pathway to form a reactive intermediate metabolite, which conjugates with glutathione and is then further metabolized to form cysteine and mercapturic acid conjugates
However, the results are typically subtle and vary significantly between individuals
If approved, commercial availability could begin in 20272028
LCCN 2024920656
Those with an additional psychiatric comorbidity other than MDD, those with any cardiac disease and any ischemic disease that may affect IMA level, those with chronic disease or neurological disease that may affect oxidative stress parameters, those with limited mental capacity and pregnant women were not included in the study because they may confound the study results
The FDA and EMA have approved a number of GLP1 receptor agonists, but in this review, we will focus on those compounds that have been investigated preclinically, that is, exenatide, liraglutide, semaglutide and dulaglutide